Literature DB >> 22933079

Experimental autoimmune encephalomyelitis.

Praveen Rao1, Benjamin M Segal.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nervous system that is induced in laboratory animals by the generation of an immune response against myelin epitopes. It has been used as a prototype of Th1- and/or Th17-driven, organ-specific autoimmunity and as a model for the human disease, multiple sclerosis. In this chapter we describe two classic protocols for EAE induction (active immunization and adoptive transfer of Th1- or Th17-polarized cells) in Subheadings 3.1 and 3.2, respectively. Subheading 3.3 describes methods for rating clinical disease in symptomatic animals. Subheading 3.4 includes instructions for the isolation of mononuclear cells from the inflamed spinal cords of mice with EAE. Subheading 3.5 describes a method for performing the enzyme-linked immunospot assay.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933079     DOI: 10.1007/978-1-60761-720-4_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance.

Authors:  Robert Kuo; Eiji Saito; Stephen D Miller; Lonnie D Shea
Journal:  Mol Ther       Date:  2017-04-10       Impact factor: 11.454

2.  Genistein modulates the expression of Toll-like receptors in experimental autoimmune encephalomyelitis.

Authors:  Alyria Teixeira Dias; Sandra Bertelli Ribeiro de Castro; Caio César de Souza Alves; Marcilene Gomes Evangelista; Luan Cristian da Silva; Daniele Ribeiro de Lima Reis; Marco Antonio Machado; Maria Aparecida Juliano; Ana Paula Ferreira
Journal:  Inflamm Res       Date:  2018-04-23       Impact factor: 4.575

3.  Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.

Authors:  Eiji Saito; Robert Kuo; Ryan M Pearson; Nishant Gohel; Brandon Cheung; Nicholas J C King; Stephen D Miller; Lonnie D Shea
Journal:  J Control Release       Date:  2019-02-27       Impact factor: 9.776

Review 4.  Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.

Authors:  Matthew W Klinker; Cheng-Hong Wei
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

5.  A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data?

Authors:  Kerrie Vaughan; Bjoern Peters; Kevin C O'Connor; Roland Martin; Alessandro Sette
Journal:  J Neuroimmunol       Date:  2013-12-12       Impact factor: 3.478

6.  Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Authors:  Ding Chen; Monica Blazek; Sara Ireland; Sterling Ortega; Xiangmei Kong; Anouk Meeuwissen; Ann Stowe; Laura Carter; Yue Wang; Ronald Herbst; Nancy L Monson
Journal:  J Immunol       Date:  2014-10-03       Impact factor: 5.422

Review 7.  Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models.

Authors:  Taryn E Mockus; Ashley Munie; Jeffrey R Atkinson; Benjamin M Segal
Journal:  J Immunol       Date:  2021-01-01       Impact factor: 5.422

8.  CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation.

Authors:  James M Nichols; Evangel Kummari; Jessica Sherman; Eun-Ju Yang; Saphala Dhital; Christa Gilfeather; Gabriella Yray; Timothy Morgan; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-21       Impact factor: 7.285

Review 9.  Mast cells and neuroinflammation.

Authors:  Hongquan Dong; Xiang Zhang; Yanning Qian
Journal:  Med Sci Monit Basic Res       Date:  2014-12-21

10.  Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway.

Authors:  Yuan Zhang; Xing Li; Bogoljub Ciric; Cun-Gen Ma; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.